| Autor: |
Propel, Investigators, Thommes, J, Najera, I, Chen, Yc, Munson, Ml, Ipe, D, Vierling, J, Pockros, P, Bzowej, N, Rodriguez Torres, M, Zeuzem, S, Mm, Ma, Ferenci, P, Herring, R, Jensen, D, Wedemeyer, H, Agarwal, K, Andreone, P, Benhamou, Y, Berg, T, Bloomer, J, Bronowicki, J, Brunetto, MAURIZIA ROSSANA, Bruno, S, Calleja, Jl, Iglesias, Ma, Cheng, W, Ciancio, A, Clark, V, Crawford, D, de Lédinghen, V, Desmond, P, Diago, M, Dikopoulos, N, Freilich, B, Godofsky, E, Hassanein, T, Hézode, C, Jacobson, I, Klass, Dm, Kuo, A, Lee, Ss, Leggett, B, Macdonald, Ga, Mac Quillan, G, Marotta, P, Vila, R, Pol, S, Ramji, A, Rasenack, Jw, Ratziu, V, Roberts, S, Romero Gómez, M, Rosenberg, W, Rossaro, L, Salmeron, Fj, Sánchez Tapias, Jm, Sanyal, Aj, Scuteri, A, Sepe, T, Sheikh, A, Sherman, M, Simon, Gl, Slim, J, Smith, Jp, Solà, R, Strasser, Si, Strohecker, J, Sulkowski, M, Tran, A, Willems, B, Yoshida, E, Zachoval, R, Zarski, J. . |
| Jazyk: |
angličtina |
| Rok vydání: |
2013 |
| Předmět: |
|
| Popis: |
Mericitabine is a nucleoside analog polymerase inhibitor of hepatitis C virus (HCV). Treatment-naive HCV genotype 1 or 4 patients were randomized to double-blind treatment with oral mericitabine at a dosage of 500 mg twice-daily (BID) for 12 weeks (A), 1,000 mg BID for 8 (B) or 12 weeks (C and D), or placebo BID for 12 weeks (E). All patients received pegylated interferon alpha-2a (Peg-IFNα-2a; 40 kD)/ribavirin (RBV) at standard doses for 24 or 48 weeks during and after mericitabine/placebo therapy. Patients in arms A-C who maintained a virologic response (VR) (HCV RNA |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
